Levodopa prodrug mesylate, compositions thereof, and uses...

Details Levodopa prodrug mesylate, compositions thereof, and uses... Levodopa prodrug mesylate, compositions thereof, and uses...

2011-02-22

2011-02-22

Keys, Rosalynd (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S533000, C514S534000, C514S537000

Reexamination Certificate

active

07893105

ABSTRACT:
(2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.

REFERENCES:
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4038411 (1977-07-01), Saari
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4093709 (1978-06-01), Choi et al.
patent: 4134991 (1979-01-01), Wermuth
patent: 4180509 (1979-12-01), Metcalf et al.
patent: 4311706 (1982-01-01), Bodor et al.
patent: 4663349 (1987-05-01), Repta
patent: 4771073 (1988-09-01), Repta
patent: 4826875 (1989-05-01), Chiesi
patent: 4873263 (1989-10-01), Repta
patent: 4914222 (1990-04-01), Budavari et al.
patent: 4966915 (1990-10-01), Tsuchiya et al.
patent: 4983400 (1991-01-01), Dempski et al.
patent: 5017607 (1991-05-01), Chiesi
patent: 5057321 (1991-10-01), Edgren et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5128145 (1992-07-01), Edgren et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5190763 (1993-03-01), Edgren et al.
patent: 5283352 (1994-02-01), Backstrom et al.
patent: 5332576 (1994-07-01), Mantelle
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5607969 (1997-03-01), Milman et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5827819 (1998-10-01), Yatvin et al.
patent: 5840756 (1998-11-01), Cohen et al.
patent: 6696600 (2004-02-01), Frenkel et al.
patent: 7101912 (2006-09-01), Xiang et al.
patent: 7323585 (2008-01-01), Xiang et al.
patent: 7342131 (2008-03-01), Xiang et al.
patent: 7534813 (2009-05-01), Xiang et al.
patent: 7563821 (2009-07-01), Xiang et al.
patent: 2002/0099041 (2002-07-01), Gallop et al.
patent: 2003/0152628 (2003-08-01), Licht et al.
patent: 2003/0158254 (2003-08-01), Zerangue et al.
patent: 2005/0209181 (2005-09-01), Akil et al.
patent: 2005/0282891 (2005-12-01), Xiang et al.
patent: 2006/0020028 (2006-01-01), Xiang et al.
patent: 2007/0225366 (2007-09-01), Xiang et al.
patent: 2008/0070984 (2008-03-01), Tran et al.
patent: 2008/0103200 (2008-05-01), Xiang et al.
patent: 2008/0132570 (2008-06-01), Xiang et al.
patent: 2008/0171789 (2008-07-01), Xiang et al.
patent: 2008/0214663 (2008-09-01), Xiang et al.
patent: 2009/0137834 (2009-05-01), Xiang et al.
patent: 2009/0156679 (2009-06-01), Xiang et al.
patent: 2 607 198 (2006-11-01), None
patent: 0 309 827 (1989-04-01), None
patent: 1447599 (1976-08-01), None
patent: 1537951 (1979-01-01), None
patent: 58-024547 (1983-02-01), None
patent: WO 86/04579 (1986-08-01), None
patent: WO 88/01615 (1988-03-01), None
patent: WO 01/68065 (2001-09-01), None
patent: WO 02/28882 (2002-04-01), None
patent: WO 2007/087256 (2007-08-01), None
U.S. Appl. No. 12/726,978, filed Mar. 18, 2010.
Alpert and Friedhoff, Paradoxical reaction to L-dopa in schizophrenic patients,Am J Psychiatry1978, 135(11), 1329-1332.
Bai, pGlu-L-Dopa-Pro: A Tripeptide Prodrug Targeting the Intestinal Peptide Transporter for Absorption and Tissue Enzymes for Conversion.Pharm. Res.1995, 12(7), 1101-1104.
Betarbet et al.,Bioessays2002, 24(4), 308-18.
Berg et al., Pharmaceutical Salts,J. Pharm. Sci.vol. 66, No. 1, Jan. 1977, 19 pages.
Bodor et al., Improved Delivery through Biological Membranes. 4. Prodrugs of L-Dopa.J. Med. Chem.1977, 20(11):1435-1445.
Boivin and Montplaisir, The effects of L-dopa on excessive daytime sleepiness in narcolepsy.Neurology1991, 41:1267-1269.
Bonelli and Wenning, Pharmacological Management of Huntington's disease: an evidence-based review,Current Pharmaceutical Design2006, 12(21), 2701-2720.
Bruno and Bruno, Effects of L-dopa on pharmacological parkinsonism,Acta Psychiatr Scand1966, 264-271, vol. 42.
Buchanan et al., Double blind trial of L-dopa in chronic schizophrenia,.Aust N Z J Psychiatry1975, 9(4), 269-271.
Cho et al.,Biochem. Biophys. Res. Commun2006, 341, 6-12.
Coleman et al., “A practical guide to polymer miscibility,”Polymer1990, 31, 1187-1203.
Conti et al., Levodopa for idiopathic restless legs syndrome: evidence-based review,Mot Disord2007, 22(13), 1943-1951.
Cools, Dopaminergic modulation of cognitive function-implications for L-dopa treatment in Parkinson's disease.Neuroscience Biobehavioral Rev2006, 30, 1-23.
Cooper et al., L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.J. Pharm. Pharmacol.39:627-635 (1987).
Di Stefano et al., Dimeric L-Dopa Derivatives as Potential Prodrugs.Bioorganic&Medicinal Chem. Lett.11:1085-1088 (2001).
Durif et al., Mov Disord 1999, 14, 242-245.
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,”Ann. Neurol.25(4):351-356 (1989).
Ebadi and Srinivasan, Pathogenesis, prevention and treatment of neuroleptic-induced movement disorders, Pharmacological Reviews 1995, 47(4), 575-604.
Eltayb et al., Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjuncitve low-dose L-dopa.Biol Psychiatry2005, 58, 337-343.
Emborg, J. Neuro. Meth. 2004, 139, 121-143.
Fahn et al., Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351(24), 2498-2508.
Fincher, J., “Particle Size of Drugs and Its Relationship to Absorption and Activity,”J. Pharm. Sci.57(11):1825-1835 (1968).
Fix et al., Short-Chain Alkyl Esters of L-Dopa as Prodrugs for Rectal Absorption.Pharm. Res.1989, 6(6), 501-505.
Fix et al., A Comparison of Oral and Rectal Absorption of L-Dopa Esters in Rats and Mice.Pharm. Res.1990, 7(4), 384-387.
Floel et al., Dopaminergic effects on encoding of a motor memory in chronic stroke,Neurology2005, 65(3), 472-474.
Floel et al., Levodopa increases memory encoding and dopamine release in the striatum in the elderly,Neurobiology of Aging2008, PMID 17098331.
Folstein et al.,J Psychiatr Res1975, 12, 189-198.
Garzon-Aburbeh et al., A Lymphotropic Prodrug of L-Dopa: Synthesis, Pharmacological Properties, and Pharmacokinetic Behavior of 1,3-Dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2,3-triol.J. Med. Chem.1986, 29, 687-691.
Gelb et al.,Arch Neurol1999, 56(1), 33-9.
Gerlach and Luhdorf, The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs.Psychopharmacologia1975, 44(1), 105-110.
Gibb et al.,J Neurol Neurosurg Psychiatry1988, 51, 745-752.
Giovanni et al.,J Neurol Neurosurg Psychiatry1999, 67, 624-629.
Hirsch et al., J Neural Transm Suppl 2003, 65, 89-100.
Hisaka et al., Absorption of a Novel Prodrug of L-Dopa, L-3-(3-Hydroxy-4-Pivaloyloxyphenyl)alanine (NB-355): In Vitro and In Situ Studies,.Drug Metabolism and Disposition1990, 18(5), 621-625.
Hogl et al., Increased daytime sleepiness in Parkinson's disease: a questionnaire survey,Movement Disorders2003, 18(3), 319-323.
Howard et al., Intracerebral drug delivery in rats with lesion-induced memory deficits.J. Neurosurg1989,71:105-112.
Inanaga et al., Double-blind controlled study of L-dopa therapy in schizophrenia, Folia Psychiatr Neurol Jpn 1975, 29(2), 123-143.
Ishikura et al., “Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds,”Int'l. J. Pharmaceutics116:51-63 (1995).
Jankovic, Treatment of dystonia, Lancet Neurol 2006, 5(10), 864-872.
Jaskiw and Popli, A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications,Psychopharmacology2004, 171, 365-374.
Juncos et al., “Levodopa methyl ester treatment of Parkinson's disease,”Neurology37:1242-1245 (1987).
Kay and Opler, L-dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study,Int'l J Psychiatry Med1985-86, 15(3), 293-298.
Knecht et al., Levodopa: faster and better wor

Affiliated with

Also associated with

Rating

Levodopa prodrug mesylate, compositions thereof, and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Levodopa prodrug mesylate, compositions thereof, and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Levodopa prodrug mesylate, compositions thereof, and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2647976